Open Accessibility Menu

DCH Urology Offers iTind Procedure for Novel BPH Treatment

  • Category: DCH
  • Posted On:
DCH Urology Offers iTind Procedure for Novel BPH Treatment

DCH Urology Offers iTind Procedure for Novel BPH Treatment

A new minimally invasive way to reshape an enlarged prostate as an alternative to surgery, drugs and permanent implants

Washington, IN (March 7, 2023) – Daviess Community Hospital Urology clinic is now using the iTind procedure to treat the symptoms of enlarged prostate. The iTind received FDA de Novo classification as a novel device for the minimally invasive treatment of Benign Prostatic Hyperplasia (BPH) in February 2020. Dr. Kris Gunn, Board-Certified Urologist is the first provider in Indiana to offer this new procedure.

BPH, also known as an enlarged prostate, is one of the most common diseases in aging men and the most common cause of lower urinary tract symptoms (LUTS).[i] According to the American Urological Association, BPH is a condition that 8 out of 10 men will face in their lifetimes, with more than half of men over the age of 50 showing symptoms.[ii] The iTind procedure reshapes the anatomy of the prostatic urethra, gently creating a wider opening for urine to flow freely, without burning or cutting out tissue, and without leaving behind a permanent implant. The treatment is straightforward, does not require overnight hospitalization, and has none of the side effects associated with prescription medication.

“I’m excited to be able to offer this new office-based procedure to treat men who are suffering from common symptoms of an enlarged prostate and want a solution that has been shown to not compromise sexual function,” said Dr. Kris Gunn.iii

“We are very proud to have Dr. Kris Gunn on staff, as the first provider in Indiana to offer the iTind,” says Tracy Conroy, CEO at Daviess Community Hospital. “The iTind gives patients at DCH the option to choose a less invasive treatment with no major side effects.”iii

For more information about DCH Urology clinic’snew BPH treatment using the iTind, please call 812-254-2872 or visit

About Olympus Medical Systems Group

Olympus is passionate about the solutions it creates for the medical, life sciences, and industrial equipment industries, as well as cameras and audio products.

Olympus’ Medical business uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients. Olympus’ Medical portfolio includes endoscopes, laparoscopes, and video imaging systems, as well as surgical energy devices, system integration solutions, medical services, and a wide range of endotherapy instruments. For more information, visit

About Medi-Tate

Medi-Tate is an Israeli medical device company that deals in the R&D, manufacture and sale of innovative solutions for the treatment of Lower Urinary Tract Symptoms (LUTS) with a mission to commercialize a safe and effective, office-based solution for BPH. For more information, visit


[i] Lim KB. Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol. 2017;4(3), 148–151. doi:10.1016/j.ajur.2017.06.004

[ii] Medical Student Curriculum: Benign Prostatic Hyperplasia (BPH). Published May 2013, Updated July 2016. Accessed March 3, 2020.

iii Kadner G, Valerio M, Giannakis I, Manit A, Lumen N, Ho BSH, Alonso S, Schulman C, Barber N, Amparore D, Porpiglia F. Second generation of temporary implantable nitinol device (iTind) in men with LUTS: 2 year results of the MT-02-study. World J Urol. 2020 Mar 2. PMID: 32124019.